Home › Marginal Zone Lymphoma › Florida
Marginal Zone Lymphoma clinical trials in Florida
15 studies for Marginal Zone Lymphoma are looking for participants at sites in Florida.
Cities in Florida
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
- Moffitt Cancer Center, Tampa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06350318A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Jacksonville, Jacksonville
- Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
- Tampa General Hospital Cancer Institute, Tampa
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables
- UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
- and 7 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04840602Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
- University of Miami, Miami
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05296070A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Boca Raton Clinical Research (BRCR) Global, Plantation
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT06149286Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Jacksonville
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- Mayo Clinic, Jacksonville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07424833A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Miami, Miami
- Florida Cancer Specialists, Sarasota
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
- University of Miami, Miami
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT05700149Study of SGR-1505 in Mature B-Cell Neoplasms
- Napa Research, Pompano Beach
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Mayo Clinic in Florida, Jacksonville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06191887AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Mount Sinai Comprehensive Cancer Center, Miami Beach
- Moffitt Cancer Center, Tampa
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT05602363Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
- University of Miami, Miami
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 28, 2025 · NCT06796998SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Jacksonville
- Massive Bio SYNERGY-AI site, Miami
- Massive Bio SYNERGY-AI site, Tampa
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Florida Cancer Specialists, Sarasota
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2025 · NCT05780034From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.